For primary human MM samples, the percentage of the subpopulation of CD138+ cells decreased by more than 42% in 16 of 16 primary myeloma samples after Bi-CAR-T treatment (Fig. 5g). The gene discussed is SDC1; the disease is Miyoshi myopathy.